vaccines-world-2017-scientifictracks-abstracts

7 / 15

alliedacademies
Virology Research Journal
Volume 1 Issue 4 Vaccines World 2017
Notes:
Page 19
November 09-10, 2017 Vienna, Austria
21st World Congress and Exhibition on
VACCINES, VACCINATION & IMMUNIZATION
Live-recombinant measles virus vaccine to prevent
zika virus infection
Sabrina Schrauf, Katrin Ramsauer, Raimund Vielnascher, Alexander Kort,
Matthias Müllner, and Erich Tauber
Themis Bioscience GmbH, Austria
Zika virus is an emerging mosquito-borne flavivirus . The
virus emerged in the past 70 years only sporadically with
self-limiting small outbreaks. In 2013, a large outbreak in
French Polynesia resulted in over 30,000 cases. Since early
2015 Zika virus spread in the Americas and to date caused
autochthonous, vector-borne transmission in 48 countries and
territories. This rapid emergence of the previously unknown
pathogen raised the urgent need for a vaccine that can be
rapidly produced in response to a newly emerging pathogen.
Themis took the challenge and developed a vaccine candidate
fromdesign toPhase 1 clinical trial within14months.TheMV-
ZIKA vaccine candidate is a live attenuated recombinant viral
vectored vaccine for the prophylaxis of Zika virus infection.
The measles virus (MV) Schwarz vaccine strain was used as
the backbone into which nucleotide sequences encoding Zika
virus structural proteins glycoprotein precursor (prM) and
the Envelope (E) were inserted to produce the MV-ZIKA. In
measles virus susceptible mice, single or multiple vaccinations
with MV-ZIKA induced a robust protective immunity, as
shown by the induction of ZIKV E protein specific antibodies.
The immunization of Cynomolgus macaques resulted in
the induction of Zika virus neutralizing antibodies in all
vaccinated animals. To evaluate the optimal dose of MV-
ZIKA regarding immunogenicity, safety, and tolerability we
initiated a double blinded, randomized, placebo-controlled,
multi-center, phase 1 trial in 48 healthy volunteer subjects.
The subjects will receive one or two vaccinations. The
immunogenicity as confirmed by the presence of functional
antibodies will be determined on day 28 after the second
immunization. The clinical trial is currently ongoing and
preliminary data will be presented here.
Biography
Sabrina Schrauf graduated as PhD from the University of Vienna in the field
of Virology where she worked on Flavivirus biology including Tick-borne
encephalitis virus and West Nile virus. She joined Themis in 2015 to coordinate
preclinical development of vaccines-vaccine design and testing.
Sabrina Schrauf et al., Virol Res J 2017, 1:4